Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.

Francisca, Reynold D C; Baba, Emna; Hoeve, Christina E; Zomerdijk, Inge M; Sturkenboom, Miriam C J M; Straus, Sabine M J M

Francisca, Reynold D C; Baba, Emna; Hoeve, Christina E; Zomerdijk, Inge M; Sturkenboom, Miriam C J M; Straus, Sabine M J M.

Afiliación

Francisca RDC; Erasmus Medical Centre, Department of Medical Informatics, Rotterdam, The Netherlands. r.francisca@erasmusmc.nl.
Baba E; Medicines Evaluation Board, Department of Pharmacovigilance, Utrecht, The Netherlands. r.francisca@erasmusmc.nl.
Hoeve CE; Medicines Evaluation Board, Department of Pharmacovigilance, Utrecht, The Netherlands.
Zomerdijk IM; Erasmus Medical Centre, Department of Medical Informatics, Rotterdam, The Netherlands.
Sturkenboom MCJM; Medicines Evaluation Board, Department of Pharmacovigilance, Utrecht, The Netherlands.
Straus SMJM; Erasmus Medical Centre, Department of Medical Informatics, Rotterdam, The Netherlands.

Drug Saf ; 44(1): 63-72, 2021 01.

Article en En | MEDLINE | ID: mdl-33000427

Asunto(s)

Aprobación de Drogas; Estadios del Ciclo de Vida; Animales; Europa (Continente); Unión Europea; Humanos; Estudios Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Aprobación de Drogas / Estadios del Ciclo de Vida Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Animals / Humans País/Región como asunto: Europa Idioma: En Revista: Drug Saf Asunto de la revista: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google